Five Years Data Reinforces the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy – BMS

Bristol Myers Squibb presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.

EXPLORER-LTE is the largest and longest evaluation of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients treated with Camzyos, the most-studied cardiac myosin inhibitor (CMI) and a standard of care for patients with oHCM in New York Heart Association (NYHA) class II-III. These data add to the understanding that the effects of Camzyos are sustained for up to five years with continuous, consistent treatment. Additional presentations at ESC Congress from COLLIGO-HCM, a global retrospective real-world data study, add to the well-established real-world evidence supporting Camzyos, helping inform treatment decisions for people living with the condition.

“The EXPLORER-LTE data up to five years reflect the sustained and clinically meaningful effects of Camzyos for patients living with symptomatic oHCM,” said Anjali T. Owens, MD, Medical Director of the Center for Inherited Cardiac Disease and an Associate Professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania. “For a chronic, progressive condition that requires ongoing treatment and monitoring, long-term evidence is essential to helping clinicians better understand how a therapy may benefit patients over time.”

EXPLORER-LTE is a single-arm, open-label, dose-blinded extension of the Phase 3 EXPLORER-HCM study, evaluating the long-term safety and efficacy of Camzyos. A total of 231 patients who completed EXPLORER-HCM enrolled in the long-term extension study. A substantial portion of patients experienced sustained and clinically meaningful reduction of left ventricular outflow tract (LVOT) obstruction, improved by at least one NYHA class and experienced notable improvements in echocardiographic measures and biomarkers. No new safety signals were observed that were not observed in the primary EXPLORER-HCM study.

At 252 weeks, Camzyos treatment resulted in mean changes from baseline at initiation of the long-term extension study of -38.7 mm Hg for resting LVOT gradient and -55.6 mm Hg in Valsalva LVOT gradient. Nearly all patients (97.4%) achieved a Valsalva LVOT gradient ≤ 30 mm Hg, which is the threshold for obstruction in patients with oHCM. 69.6% of patients improved by ≥1 NYHA class and 59.2% of patients were asymptomatic. Mean left ventricular ejection fraction (LVEF) decreased by 10.2% and remained within the normal range. Safety findings were consistent with reported results from the primary EXPLORER-HCM study.

Additional data presented at ESC Congress further support Camzyos and our understanding of the impact of oHCM. Two presentations from COLLIGO-HCM, a global retrospective real-world data study, added to the well-established real-world evidence supporting Camzyos in clinical practice, with a real-world effectiveness and safety profile that is consistent across patients, providing symptom improvement and reduction in LVOT obstruction. A complementary analysis of a real-world observational registry study in Germany reinforces the effectiveness of Camzyos across geographic populations, with patients achieving NYHA class reductions consistent with previously reported real-world studies. These findings build on the existing evidence base for Camzyos and reinforce that the improvements seen in clinical trials are also achieved in real-world settings. An additional analysis of a healthcare resource utilization (HCRU) study in Sweden adds to the understanding of the broader disease burden of HCM and oHCM, including the increased impact of oHCM, and emphasizes the importance of accurate diagnosis and consistent care for patients living with oHCM.

“For people living with symptomatic oHCM, long-term and real-world evidence provides greater confidence in treatment decisions and a clearer understanding of what sustained therapy may mean over time,” said Cristian Massacesi, MD, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “As part of our dedication to advancing cardiovascular research, the data presented at ESC Congress add to the understanding and trust of Camzyos and its role in helping patients manage oHCM, a serious condition affecting daily activities for many patients.”

Camzyos is supported by the largest body of worldwide evidence in the CMI treatment class, reinforcing its role in transforming care for symptomatic oHCM by improving functional capacity and symptoms, allowing patients to be more active in their daily lives.

About EXPLORER-LTE
EXPLORER-LTE, a cohort of the MAVA-LTE study (NCT03723655), is a single-arm, open-label, dose-blinded extension of the Phase 3 EXPLORER-HCM study evaluating the long-term safety and efficacy of Camzyos. A total of 231 patients in the United States, Europe and Israel who completed EXPLORER-HCM enrolled in the long-term extension study.